# An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Source: https://onco.cc/trials/nct01368276/  
OnCo record `nct01368276` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Talimogene laherparepvec in Melanoma, run by BioVex Limited, completed.

## Summary

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma is a phase 3 interventional study registered as NCT01368276 by BioVex Limited, with 31 participants recorded, started 2010-10 and reaching its primary completion in 2014-09. Interventions recorded: Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). Conditions recorded: Melanoma.

Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01368276
- Phase: 3
- Setting: An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
- Sponsor: BioVex Limited
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT01368276: https://clinicaltrials.gov/study/NCT01368276

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct01368276.json